LLY NYSE
Eli Lilly and Company
1W: +3.1%
1M: +8.1%
3M: +4.8%
YTD: +18.6%
1Y: +56.0%
3Y: +120.0%
5Y: +457.4%
$1,283.69
+4.55 (+0.36%)
Weekly Expected Move ±4.4%
$1162
$1218
$1273
$1329
$1385
Credit Risk of going bust: lower than 84% of companies Debt: 4.4% of company value Bonds: $1.28B held by 465 funds, 44 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $5.05 (down 99.6%), Eli Lilly and Company would be worth roughly what it owes.
Total debt $54.91B against a stock market value of $1.20T.
Distance to default 10.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.98B (short-term plus half of long-term), stock volatility 34.6%; Altman Z 8.56. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $5.05 (down 99.6%), Eli Lilly and Company would be worth roughly what it owes.
Total debt $54.91B against a stock market value of $1.20T.
Distance to default 10.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.98B (short-term plus half of long-term), stock volatility 34.6%; Altman Z 8.56. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#2
of 19
Drug Manufacturers - General
Technical Signal Map
7 Bullish
0 Neutral
1 Bearish
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
ABBV
$505B
AbbVie Inc.
BULLISH
+91
RHHBF
$393B
Roche Holding AG
BULLISH
+75
NVS
$287B
Novartis AG
BULLISH
+75
AMGN
$237B
Amgen Inc.
BULLISH
+66
AZN
$266B
AstraZeneca PLC
BULLISH
+50
JNJ
$636B
Johnson & Johnson
BULLISH
+43
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
LLY vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F